If you have been reading about glucagon receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-05. Numbers and descriptions here follow the published literature rather than marketing material.
Solid material is generally held at -20 °C or colder, while reconstituted solutions are kept at 2-8 °C and used within a short window. Buffers that maintain a slightly acidic to neutral pH tend to improve short-term peptide stability. Repeated warming and cooling of stock solutions promotes aggregation and should be avoided. Container closures should remain intact, since adsorption to some plastics can reduce the amount of peptide in solution.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatographic profiles reveal related impurities, truncated sequences, and oxidation products, while mass measurement confirms the expected molecular mass. Purity values for research material are typically reported as a percentage by peak area. Reference standards help calibrate retention behavior across instruments. Independent laboratories emphasize method suitability because results depend heavily on column chemistry, gradient, and detection wavelength. Batch-to-batch comparison relies on the same validated method.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | Designed to engage three receptor targets |
| Appearance | White to off-white powder | Lyophilized form supplied in sealed vials |
| Solubility | Soluble in water | Dissolves in aqueous buffer systems |
| Storage, solid | -20 °C or below | Desiccated and protected from light |
| Typical analysis | RP-HPLC with mass detection | Purity by peak area, identity by mass |
Dissolution behavior depends on the amino acid sequence, the counterion content, and the buffer chosen. Many peptides disperse readily in water or mild aqueous buffers, while others require a small amount of organic co-solvent or a change in pH. Adsorption to plastic and glass surfaces can reduce the concentration of a solution over time, particularly at low concentrations. Filtration before analysis removes particulates, and aliquoting limits repeated freeze-thaw cycles that stress the material.
Research-grade peptide material is commonly supplied as a lyophilized powder, a form that limits degradation during transport and storage. Standard practice keeps such material cold and protected from light and moisture, with tighter conditions used for long-term archives. Once dissolved, solutions are generally considered less stable than the dry powder and are handled on shorter timescales. These established conventions derive largely from general peptide chemistry rather than from compound-specific evidence alone.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
三种受体在能量平衡中的分工并不相同：GLP-1 与 GIP 受体主要参与胰岛素分泌和食欲调节，胰高血糖素受体则与能量消耗及肝糖输出相关。同时激活三者可能产生叠加效应，也可能出现相互制约，具体结果取决于受体亲和力与组织分布。这种组合在理论上可能同时影响体重与血糖指标，但协同关系的细节仍处在研究阶段。
=== Pharmacokinetics === After injection into a vein, 14% of the circulating ioxaglic acid is bound to blood plasma proteins, which is unusually high for a water-soluble iodinated contrast agent. The substance is distributed in the body with a half-life of 12 minutes (range 4 to 17 minutes) and eliminated in unmetabolized (unchanged) form via the kidneys with a half-life of 92 minutes (range 61 to 140 minutes). In people with kidney failure, it is eliminated via the bile duct, saliva or sweat.
Substantial cephalopelvic disproportion Unfavorable fetal position or presentation (e.g., transverse lies) undeliverable without conversion before delivery Obstetric emergencies where maternal or fetal risk-to-benefit ratio favors surgery Fetal distress when delivery is not imminent Umbilical cord prolapse Uterine activity fails to progress adequately Hyperactive or hypertonic uterus Vaginal delivery is contraindicated (e.g., invasive cervical carcinoma, active genital herpes infection, total placenta previa, vasa previa, cord presentation or prolapse) Uterine or cervical scarring from previous cesarean section or major cervical or uterine (e.g., transfundal) surgery Unengaged fetal head History of hypersensitivity to oxytocin or any ingredient in the formulation
heterokaryon A multinucleate cell containing nuclei with different genotypes, resulting from the fusion of two or more genetically distinct cells, either naturally (e.g. in certain types of sexual reproduction) or artificially (e.g. in genetic engineering).
== Regulatory harmonization == In an effort to reduce the burden on manufacturers applying for orphan drug status, the FDA and the European Medicines Agency (EMA) agreed in late 2007 to utilize a common application process for both agencies. However, the two agencies will continue to maintain separate approval processes.
Moreover, a number of the key results in this field have shown that bioelectric circuits are non-local – regions of the body make decisions based on bioelectric events at a considerable distance. Such non-cell-autonomous events suggest distributed network models of bioelectric control; new computational and conceptual paradigms may need to be developed to understand spatial information processing in bioelectrically active tissues. It has been suggested that results from the fields of primitive cognition and unconventional computation are relevant to the program of cracking the bioelectric code. Finally, efforts in biomedicine and bioengineering are developing applications such as wearable bioreactors for delivering voltage-modifying reagents to wound sites, and ion channel-modifying drugs (a kind of electroceutical) for repair of birth defects and regenerative repair. Synthetic biologists are likewise starting to incorporate bioelectric circuits into hybrid constructs.
Sources: en.wikipedia.org
Serology is the scientific study of antibodies in the serum and other body fluids. Such antibodies are typically formed in response to an infection (against a given microorganism), against other foreign proteins (in response, for example, to a mismatched blood transfusion), or to one's own proteins (in instances of autoimmune disease).
==== Increasing fiber intake ==== Fruits and vegetables are two sources of fiber as discussed above. Dietary fiber has been suggested to aid weight management by inducing satiety, decreasing absorption of macronutrients and promoting secretion of gut hormones. Dietary fiber consists of non-digestible carbohydrates and lignin, which are a structural component in plants.
== Principle - separation of enantiomers == In an isotopic/achiral environment, enantiomers exhibit identical physicochemical properties, and therefore are indistinguishable under these conditions. For the separation of chiral molecules the challenge is to construct the right chiral environment. In a chromatographic system there are three variables namely, the chiral analyte (CA), mobile phase and stationary phase, that can be manipulated to provide the crucial chiral environment. The strategy is to make these variables to interact with a chiral auxiliary (chiral selector, CS) whereby it forms a diastereomeric complex which has different physicochemical properties and makes it possible to separate the enantiomers. Based on the nature of the diastereomeric complex formed between the CS-CA species, enantiomer separation mythologies are categorized as indirect and direct enantiomer separation mode
High-energy radiation from space is much stronger at high altitudes than at sea level. The radiation exposure of flight crews and air travelers is therefore increased. The International Commission on Radiological Protection (ICRP) has issued recommendations for dose limits, which were incorporated into European law in 1996 and into the German Radiation Protection Ordinance in 2001. Radiation exposure is particularly high when flying in the polar regions or over the polar route. The average annual effective dose for aviation personnel was 1.9 mSv in 2015 and 2.0 mSv in 2016. The highest annual personal dose was 5.7 mSv in 2015 and 6.0 mSv in 2016. The collective dose for 2015 was about 76 person-Sv. This means that flight personnel are among the occupational groups in Germany with the highest radiation exposure in terms of collective dose and average annual dose. This group also includes frequent flyers, with Thomas Stuker holding the "record" - also in terms of radiation exposure - by reaching the 10 million mile mark with United Airlines MileagePlus on 5,900 flights between 1982 and the summer of 2011. In 2017, he passed the 18 million mile mark. The program EPCARD (European Program Package for the Calculation of Aviation Route Dose) was developed at the University of Siegen and the Helmholtz Munich and can be used to calculate the dose from all components of natural penetrating cosmic radiation on any flight route and flight profile - also online.
== Future perspectives == New generation sequencing may be used to yield a whole genome sequence from cffDNA. This raises ethical questions. However, the utility of the procedure may increase as clear associations between specific genetic variants and disease states are discovered.
Sources: en.wikipedia.org
Solid powder is held frozen at -20 °C or below in a desiccated container. Reconstituted solutions are refrigerated and used within a limited period.
Reversed-phase liquid chromatography separates the peptide from related impurities. Mass spectrometry confirms molecular mass, which supports structural identity.
Repeated freezing and thawing can promote aggregation and precipitation of peptide material. Dividing material into single-use aliquots reduces this risk.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.